News

Dechra announces U.S. launch of Solovecin™ (cefovecin sodium), an in-clinic antibiotic solution for skin infections in dogs and cats

Ensures a full course of therapy in one, affordable injection, alleviating oral treatment compliance concerns

Dechra Expands AVMF Scholarship Program, Adding New Category Focused on Anesthesia, Surgery, and Critical Care

Over $60,000 in scholarships is now available to 20 veterinary students and 5 technicians.

On Take Your Dog to Work Day, HABRI and Dechra Partner to Strengthen the Human-Animal Bond

The Human Animal Bond Research Institute (HABRI) and Dechra, a global animal health company focused on veterinary specialty care, marked “Take Your Dog to Work Day” by announcing a new partnership to advance their shared mission of supporting the human-animal bond through research, education and advocacy.

Dechra Launches Catney® One: A New Tool for Feline Kidney Health

Catney One® provides veterinarians another option to combat phosphate absorption, a key challenge in maintaining feline kidney health

Dechra Announces FDA Approval of Otiserene® (marbofloxacin, terbinafine, and dexamethasone otic suspension) the latest treatment for canine otitis externa

First single-dose, long-acting otitis externa product leveraging marbofloxacin

One More Step for Not One More Vet

This World Vet Day (April 26, 2025), Dechra – a leading global animal health company, launched its ‘One More Step for Not One More Vet’ campaign in its continued support of a veterinary mental health charity.

Dechra Launches DuOtic®: The First Antibiotic-Free Otitis Externa Treatment for Dogs

A first-to-market, antibiotic-free approach to treating canine ear infections with long-lasting relief and increased antimicrobial stewardship

Dechra Expands Commitment to Veterinary Profession with New American Veterinary Medical Foundation Scholarships

Nearly $50,000 in scholarships continues a decade-long effort of supporting veterinary students and now expands to veterinary technicians

Dechra Pharmaceuticals Limited (Dechra) today announces the appointment of a new North American President

Laura Olsen will join Dechra as the new President of North America, effective September 9, bringing a wealth of experience in animal and human health, having previously worked at Zoetis, Pfizer, and Novartis.

Dechra Pharmaceuticals Limited (Dechra) announces the upcoming acquisition of Invetx

In line with its long-term strategy to be an innovation leader in health, Invetx specializes in developing protein-based therapeutics for companion animals' chronic conditions, focusing on monoclonal antibodies (mAbs).